Category: NTIDC News

Gilead’s New Capsid Inhibitor in Early Trials
Post

Gilead’s New Capsid Inhibitor in Early Trials

Gilead’s new capsid inhibitor GS-6207 has started its phase 1b trial with the potential for 3 month dosing. The capsid inhibitor is currently being dosed by a subcutaneous injection but Gilead is attempting to develop a oral formulation of the antiretroviral.

North Texas Infectious Diseases